methyl N-[(1R)-2-oxo-1-phenyl-2-[(6S)-6-[5-[4-[2-[2-[(6S)-5-[(2S)-2-phenylpropanoyl]-5-azaspiro[2.4]heptan-6-yl]-3H-benzimidazol-5-yl]ethynyl]phenyl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]ethyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(1R)-2-oxo-1-phenyl-2-[(6S)-6-[5-[4-[2-[2-[(6S)-5-[(2S)-2-phenylpropanoyl]-5-azaspiro[2.4]heptan-6-yl]-3H-benzimidazol-5-yl]ethynyl]phenyl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]ethyl]carbamate
• 化学式: C₄₉H₄₇N₇O₄
• 分子量: 797.9
• InChiKey: MAJSHLXFJKXBSO-DZAMKIJPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  60
• 可旋转键数：
  11
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  136
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20140193363A1

  公开（公告）日：2014-07-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.